Deep Learning-Based Proarrhythmia Analysis Using Field Potentials Recorded From Human Pluripotent Stem Cells Derived Cardiomyocytes

An early characterization of drug-induced cardiotoxicity may be possible by combining comprehensive in vitro proarrhythmia assay and deep learning techniques. We aimed to develop a method to automatically detect irregular beating rhythm of field potentials recorded from human pluripotent stem cells (hPSC) derived cardiomyocytes (hPSC-CM) by multi-electrode array (MEA) system. We included field potentials from 380 experiments, which were labeled as normal or arrhythmic by electrophysiology experts. Convolutional and recurrent neural networks (CNN and RNN) were employed for automatic classification of field potential recordings. A preparation phase was initially applied to split 60-s long recordings into a series of 5-s windows. Subsequently, the classification phase comprising of two main steps was designed and applied. The first step included the classification of 5-s windows by using a designated CNN. While, the results of 5-s window assessments were used as the input sequence to an RNN that aggregates these results in the second step. The output was then compared to electrophysiologist-level arrhythmia detection, resulting in 0.83 accuracy, 0.93 sensitivity, 0.70 specificity, and 0.80 precision. In summary, this paper introduces a novel method for automated analysis of “irregularity” in an in vitro model of cardiotoxicity experiments. Thus, our method may overcome the drawbacks of using predesigned features that restricts the classification performance to the comprehensiveness and the quality of the designed features. Furthermore, automated analysis may facilitate the quality control experiments through the procedure of drug development with respect to cardiotoxicity and avoid late drug attrition from market.

[1]  Luca Sala,et al.  Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs) , 2017, Journal of visualized experiments : JoVE.

[2]  Nick Thomas,et al.  High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Bram van Ginneken,et al.  A survey on deep learning in medical image analysis , 2017, Medical Image Anal..

[4]  Liang Guo,et al.  Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  Nitish Srivastava,et al.  Dropout: a simple way to prevent neural networks from overfitting , 2014, J. Mach. Learn. Res..

[6]  Philip Wong,et al.  Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  S. Heilmann-Heimbach,et al.  Generation of human induced pluripotent stem cell line from a patient with a long QT syndrome type 2. , 2016, Stem cell research.

[8]  Jürgen Schmidhuber,et al.  Long Short-Term Memory , 1997, Neural Computation.

[9]  Mike Clements,et al.  Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  David G Strauss,et al.  Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA. , 2017, Journal of electrocardiology.

[11]  Sergey Ioffe,et al.  Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift , 2015, ICML.

[12]  K. Aalto-Setälä,et al.  Cardiomyocyte MEA Data Analysis (CardioMDA) – A Novel Field Potential Data Analysis Software for Pluripotent Stem Cell Derived Cardiomyocytes , 2013, PloS one.

[13]  Michael A. Arbib,et al.  The handbook of brain theory and neural networks , 1995, A Bradford book.

[14]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[15]  P. Sager,et al.  Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study , 2017, Clinical pharmacology and therapeutics.

[16]  H. Baharvand,et al.  Generation of human induced pluripotent stem cells from a Bombay individual: moving towards "universal-donor" red blood cells. , 2010, Biochemical and biophysical research communications.

[17]  Ronald A. Li,et al.  Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells , 2017, eLife.

[18]  C. Mummery,et al.  Human stem cell models for predictive cardiac safety pharmacology. , 2010, Stem cell research.

[19]  Hossein Baharvand,et al.  A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells , 2015, Stem cells translational medicine.

[20]  R. Passier,et al.  Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes , 2017, Biochemical and biophysical research communications.

[21]  Liang Guo,et al.  Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Hugh S Markus,et al.  Personalized medicine: risk prediction, targeted therapies and mobile health technology , 2014, BMC Medicine.

[23]  H. Krumholz Big data and new knowledge in medicine: the thinking, training, and tools needed for a learning health system. , 2014, Health affairs.

[24]  Gary Gintant,et al.  The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery. , 2017, Cell stem cell.

[25]  H. Baharvand,et al.  Generation of new human embryonic stem cell lines with diploid and triploid karyotypes , 2006, Development, growth & differentiation.

[26]  E. Schulze-Bahr,et al.  Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction , 2016, Basic Research in Cardiology.

[27]  Geoffrey E. Hinton,et al.  Deep Learning , 2015, Nature.

[28]  U. Egert,et al.  Development of electrical activity in cardiac myocyte aggregates derived from mouse embryonic stem cells. , 2003, American journal of physiology. Heart and circulatory physiology.

[29]  Gary R. Mirams,et al.  Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies , 2017, British journal of pharmacology.

[30]  Ville J. Kujala,et al.  Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes , 2016, SpringerPlus.

[31]  Azra Fatima,et al.  In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.

[32]  K. Borgwardt,et al.  Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.

[33]  Moncef Gabbouj,et al.  Personalized Monitoring and Advance Warning System for Cardiac Arrhythmias , 2017, Scientific Reports.

[34]  Byunghan Lee,et al.  Deep learning in bioinformatics , 2016, Briefings Bioinform..

[35]  Amir Lerman,et al.  Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. , 2013, Pharmacology & therapeutics.

[36]  M. Hayden,et al.  Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes , 2016, Scientific Reports.

[37]  K. Aalto-Setälä,et al.  The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes , 2016, Stem Cell Reviews and Reports.

[38]  K. Harris,et al.  A Human Induced Pluripotent Stem Cell−Derived Cardiomyocyte (hiPSC‐CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening , 2015, Current protocols in pharmacology.

[39]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[40]  R. Harvey,et al.  Large-Scale Production of Cardiomyocytes from Human Pluripotent Stem Cells Using a Highly Reproducible Small Molecule-Based Differentiation Protocol. , 2016, Journal of visualized experiments : JoVE.

[41]  G. Gintant,et al.  Evolution of strategies to improve preclinical cardiac safety testing , 2016, Nature Reviews Drug Discovery.

[42]  T. Šarić,et al.  Effects of hawthorn (Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia‐specific induced pluripotent stem cells , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Tetsuji Itoh,et al.  CSAHi study‐2: Validation of multi‐electrode array systems (MEA60/2100) for prediction of drug‐induced proarrhythmia using human iPS cell‐derived cardiomyocytes: Assessment of reference compounds and comparison with non‐clinical studies and clinical information , 2017, Regulatory toxicology and pharmacology : RTP.

[44]  Alex Graves,et al.  Supervised Sequence Labelling , 2012 .

[45]  M. Morad,et al.  Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. , 2013, Cell calcium.

[46]  A. Su,et al.  Harnessing the heart of big data. , 2015, Circulation research.